Jafron Biomedical Co Ltd (300529) - Total Assets
Based on the latest financial reports, Jafron Biomedical Co Ltd (300529) holds total assets worth CN¥5.54 Billion CNY (≈ $810.11 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Jafron Biomedical Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Jafron Biomedical Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Jafron Biomedical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Jafron Biomedical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jafron Biomedical Co Ltd's total assets of CN¥5.54 Billion consist of 51.7% current assets and 48.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 32.0% |
| Accounts Receivable | CN¥59.27 Million | 1.1% |
| Inventory | CN¥337.79 Million | 6.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥97.75 Million | 1.8% |
| Goodwill | CN¥7.01 Million | 0.1% |
Asset Composition Trend (2011–2024)
This chart illustrates how Jafron Biomedical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Jafron Biomedical Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jafron Biomedical Co Ltd's current assets represent 51.7% of total assets in 2024, a decrease from 85.6% in 2011.
- Cash Position: Cash and equivalents constituted 32.0% of total assets in 2024, down from 71.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 6.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 6.3% of total assets.
Jafron Biomedical Co Ltd Competitors by Total Assets
Key competitors of Jafron Biomedical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.15 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $139.92 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs8.57 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩45.11 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr48.33 Million |
Jafron Biomedical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.26 | 3.77 | 6.01 |
| Quick Ratio | 3.80 | 3.41 | 5.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.23 Billion | CN¥2.42 Billion | CN¥1.66 Billion |
Jafron Biomedical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jafron Biomedical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.03 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | CN¥5.38 Billion |
| Market Capitalization | $2.23 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Jafron Biomedical Co Ltd's assets below their book value (0.41x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Jafron Biomedical Co Ltd's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jafron Biomedical Co Ltd (2011–2024)
The table below shows the annual total assets of Jafron Biomedical Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.38 Billion ≈ $787.77 Million |
-2.88% |
| 2023-12-31 | CN¥5.54 Billion ≈ $811.16 Million |
+2.40% |
| 2022-12-31 | CN¥5.41 Billion ≈ $792.15 Million |
+12.54% |
| 2021-12-31 | CN¥4.81 Billion ≈ $703.87 Million |
+49.54% |
| 2020-12-31 | CN¥3.22 Billion ≈ $470.70 Million |
+28.94% |
| 2019-12-31 | CN¥2.49 Billion ≈ $365.05 Million |
+21.57% |
| 2018-12-31 | CN¥2.05 Billion ≈ $300.27 Million |
+20.53% |
| 2017-12-31 | CN¥1.70 Billion ≈ $249.11 Million |
+30.97% |
| 2016-12-31 | CN¥1.30 Billion ≈ $190.21 Million |
+88.75% |
| 2015-12-31 | CN¥688.67 Million ≈ $100.77 Million |
+27.77% |
| 2014-12-31 | CN¥539.01 Million ≈ $78.87 Million |
+16.74% |
| 2013-12-31 | CN¥461.73 Million ≈ $67.57 Million |
+35.17% |
| 2012-12-31 | CN¥341.58 Million ≈ $49.98 Million |
+38.72% |
| 2011-12-31 | CN¥246.24 Million ≈ $36.03 Million |
-- |
About Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification ma… Read more